ACHV

Achieve Life Sciences, Inc. (ACHV) - 10-K Summary

Business Context and Reporting Period

Company: Achieve Life Sciences, Inc.
Reporting Period: Fiscal year ended December 31, 2024
Business Model: Late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline, a plant-based alkaloid for smoking and e-cigarette (vaping) cessation.
Key Milestone: The company completed enrollment for the ORCA-OL open-label safety trial in October 2024 and achieved the goal of 300 subjects completing six months of cumulative treatment in January 2025. The company expects to file a New Drug Application (NDA) with the FDA for smoking cessation in the second quarter of 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $10 million year-over-year, driven primarily by higher R&D expenses due to the initiation of the ORCA-OL safety trial and increased G&A expenses related to stock-based compensation, severance, and commercial launch preparations.
• Debt Refinancing: In July 2024, the company entered into a new $10.0 million convertible term loan with Silicon Valley Bank (SVB), refinancing the previous debt. This resulted in a $0.3 million loss on extinguishment of the prior debt.
• Cash Position: Cash and marketable securities increased significantly to $34.4 million from $15.5 million, bolstered by a February 2024 registered direct offering that raised approximately $56.1 million in net proceeds.
• Contingent Consideration: The fair value of the contingent consideration liability to Sopharma increased to $1.1 million from $0.5 million, resulting in a $0.6 million loss for the year.

Guidance, Outlook, and Risks

• Going Concern: The company has expressed substantial doubt about its ability to continue as a going concern. Current resources are insufficient to fund planned operations for the next 12 months. Continued operations depend on raising additional capital.
• Regulatory Outlook: Management expects to submit an NDA for smoking cessation in Q2 2025. The company received Breakthrough Therapy Designation from the FDA for cytisinicline for vaping cessation in Q3 2024.
• Capital Requirements: The company anticipates incurring significant expenses and increasing operating losses for the foreseeable future as it advances clinical development and prepares for commercialization.
• Key Risks:
  • Single Product Candidate: The business relies entirely on cytisinicline; failure to obtain approval or commercialize would be fatal to the business.
  • Supply Chain: The company relies exclusively on Sopharma AD in Bulgaria for the manufacture of cytisinicline. Geopolitical instability or supply disruptions could halt development.
  • Debt Obligations: The company has substantial debt with floating interest rates. Failure to service debt could lead to default and foreclosure on assets.
  • Intellectual Property: Cytisinicline is a naturally occurring substance and not patentable in the U.S. as a composition of matter; protection relies on formulation patents and regulatory exclusivity.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for when current cash reserves ($34.4 million) will be depleted and the status of any new financing efforts.
• NDA Submission Date: Confirm the Q2 2025 NDA filing timeline and any potential delays related to the ORCA-OL trial data review.
• Debt Covenants: Review the specific covenants in the new SVB debt agreement, particularly regarding cash concentration requirements and conversion triggers.
• Supply Agreement: Assess the stability of the supply agreement with Sopharma AD and any contingency plans for manufacturing disruptions.
• Dilution Risk: Evaluate the potential dilution from the outstanding convertible debt ($10M principal), warrants (~17.5M shares), and options (~2.1M shares).